Epidermal growth factor receptor (EGFR) antisense transfection reduces the expression of EGFR and suppresses the malignant phenotype of a human ovarian cancer cell line.
An EGFR-expressing clone of the human ovarian cancer line 2774 was transfected with an antisense construct of EGFR to test how suppression of this gene modulates the malignant phenotype. Transfected clones were screened for EGFR expression by Western blot and FACS analysis. Anchorage-independent growth was used to assess the effect of reduced EGFR on the malignant behavior of the cells. Several transfected clones with decreased EGFR (40-50% reduction) were identified. A correlation was noted between reduced EGFR and decreased anchorage-independent growth, with the transfected clones losing the ability to grow in agarose and responsiveness to exogenous EGF. These results suggest that EGFR may be an important factor in the malignant behavior of this ovarian cancer cell line.
Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
K R
KR
Brader
J K
JK
Wolf
S
S
Chakrabarty
J E
JE
Price
D002455:Cell Division; D002999:Clone Cells; D016373:DNA, Antisense; D066246:ErbB Receptors / Q000096:biosynthesis / Q000235:genetics*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007700:Kinetics; D010051:Ovarian Neoplasms; D014158:Transcription, Genetic; D014162:Transfection; D014407:Tumor Cells, Cultured
D016373:DNA, Antisense; D066246:ErbB Receptors